medigraphic.com
ISSN 1561-3062 (Electronic)

2022, Number 2

Next >>

Revista Cubana de Obstetricia y Ginecología 2022; 48 (2)

COVID-19 and Use of Emergency Vaccination in Pregnancy

Aguilar EJA, Anaya HCA, Trujillo RM, Navarro ME, Sosa LM

Language: Spanish
References: 35
Page:
PDF size: 437.74 Kb.


ABSTRACT

Introduction: COVID-19 is a respiratory infection of viral origin that was diagnosed for the first time at the end of 2019 in China. In Cuba, pregnant women were part of the population group with the highest morbidity.
Objective: To present updated information on COVID-19 and the relationship with the use of emergency vaccination during pregnancy.
Methods: A search was performed in SciELO, PubMed, Medline, and DynaMed, using the terms SARS-CoV-2, COVID-19, vaccines, and pregnancy. One hundred twenty three documents were retrieved, 36 of them were castoff because they did not correspond with the theme of this review. Out of the remaining 87, 19 were not useful because the full text was not accessible and 23 were not considered reliable due to the methodology used. We selected 35 out of the remaining.
Conclusions: The physiological changes of pregnancy put the pregnant woman affected by COVID-19 at greater risk for severe or critical stages of the disease, which can lead to a high lethality. Espirta study designed by the Genetic Engineering and Biotechnology Center of Havana is part of the surveillance strategy and it will evaluate the immunogenicity achieved by pregnant women and their newborns.


REFERENCES

  1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 [acceso 10/05/2022];356(9237):1255-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11072960/

  2. Minsap. Protocolo vs COVID-19. La Habana: Minsap; 2020 [acceso 10/05/2022]. p. 15. Disponible en: https://covid19cubadata.github.io/#cuba

  3. Ahn DG, Shin HJ, Kim HS, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020 [acceso 12/05/2022];30(3):313-24. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32238757/

  4. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2021 [acceso 11/05/2022];54(2):159-63. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32265180/

  5. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int. J. Antimicrob. Agents. 2020 [acceso 25/04/2022];55(5):8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32234466/

  6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 [acceso 23/04/2022];395(10223):507-13. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32007143/

  7. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020 [acceso 29/04/2022];39(6):1011-19: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32291542/

  8. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 [acceso 02/05/2022];395(10223):497-506. Disponible en: https://facultyopinions.com/article/73725313

  9. Centro de Coordinación de Alertas y Emergencias Sanitarias. Información científica-técnica. Enfermedad por coronavirus, COVID-19 en distintos entornos y grupos de personas. Ministerio de Sanidad. España: CCAES; 2021 [acceso 03/05/2022]. p. 16. Disponible en: https://www.aemps.gob.es/

  10. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011 [acceso 22/04/2022];20(1):62-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21099686/

  11. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009 [acceso 02/04/2022];2(5):446-55: Disponible en: https://pubmed.ncbi.nlm.nih.gov/19808375/

  12. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 [acceso 03/05/2022];63(3):364-74. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32048163/

  13. Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options Microbial Pathogenesis and therapeutic options. Microb Pathog. 2021 [acceso 23/05/2022];150:16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33278517/

  14. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 [acceso 23/05/2022];395(10229):1033-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32192578/

  15. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 [acceso 23/05/2022];9(1):727-32. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32196410/

  16. Othman SI, Nayel MA, Alwaele MA, Al FassamH, Abu-Taweel GM, Altoom NG, et al. Immunology and controlling of coronaviruses; the current enemy for humanity: A review. Int. J. Biol. Macromol. 2021 [acceso 21/04/2022];193:1532-40. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34732305/

  17. Cohen J. The immunopathogenesis of sepsis. Nature. 2002 [acceso 21/04/2022];420(6917):885-91. Disponible en: https://pubmed.ncbi.nlm.nih.gov/12490963/

  18. Segura Fernández A, León Cid I, Urgellés Carrera S, Ramos Zamora V, Herrera Frómeta Y, Rodríguez Columbié, et al. Caracterización clínica de las pacientes obstétricas con sospecha de COVID-19. Rev. Cub. Med. Milit. 2020 [acceso 07/06/2022];49(3):9. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/796

  19. Heath PT, Le Doare K, Khalil A. Inclusion of pregnant women in COVID-19 vaccine development. Lancet Infect Dis. 2020 [acceso 07/06/2022];20(9):1007-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32795409/

  20. International Federation of Gynecology and Obstetrics. COVID-19 Vaccination for Pregnant and Breastfeeding Women. FIGO. 2021 [acceso 07/06/2022]. Disponible en: https://www.figo.org/covid-19-vaccination-pregnant-and-breastfeeding-women

  21. Obstetrics Ginecology University of Washington. Vaccinating Pregnant and Lactating Patients against COVID-19. 2021. UW Medic. 2021 [acceso 07/06/2022]:12. Disponible en: https://obgyn.uw.edu/news/vaccinating-pregnant-and-lactating-patients-against-covid-19

  22. Gill L, Jones CW. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy. Obstet Gynecol. 2021 [acceso 07/06/2022]:137(5):894-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33684922/

  23. Martínez Portilla RJ, Sotiriadis A, Chatzakis C, Torres Torres J, Espino Y, Sosa S, et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol. 2021 [acceso 07/06/2022];57(2):224-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33320401/

  24. Carrillo Mora P, García Franco A, Soto Lara M, Rodríguez Vásquez G, Pérez Villalobos J, Martínez Torres D. Cambios fisiológicos durante el embarazo normal. Rev. Fac. Med. (Méx). 2021 [acceso 07/06/2022];64(1):39-48. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttex&pid=S0026-17422021000100039&Ing=es

  25. Marañón Cardonne T, Mastrapa Cantillo K, Poulut Durades TM, Vaillant Lora LlD. COVID-19 y embarazo: Una aproximación en tiempos de pandemia, Medisan. 2020 [acceso 07/06/2022];24(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttex&pid=S1029-301920000400707

  26. Falsaperla R, Leone G, Familiari M, Ruggieri M. COVID-19 Vaccination in Pregnant and Lactating Women: a systematic review. Expert. Rev. Vaccines. 2021 [acceso 07/06/2022];20(12):1619-28. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34592123/

  27. FIGO. Vacunación contra la COVID-19 para mujeres embarazadas y lactantes/FIGO 2021 [acceso 07/06/2022]. Disponible en: https://www.figo.org/es/vacunacion-contra-la-COVID-19-para-mujeres-embarazadas-ylactantes

  28. Jorgensen SCJ, Burry L, Tabbara N. Role of maternal COVID-19 vaccination in providing immunological protection to the newborn. Pharmacotherapy. 2022 [acceso 07/06/2022];42(1):58-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34816467/

  29. ACOG. Vaccinating Pregnant and Lactating Patients Against COVID-19. 2021 [acceso 07/06/2022]. Disponible en: https://www.acog.org/en/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-Pregnant-and-Lactating-Patients-Against-COVID-19

  30. Abuhammad S. Attitude of pregnant and lactating women toward COVID-19 vaccination in Jordan: a cross-sectional study. J. Perinat. Med. 2022 [acceso 07/06/2022];13. Disponible en: https://www.degruyter.com/document/doi/10.1515/jpm-2022-0026/html

  31. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 [acceso 07/06/2022];584(7819):115-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32454513/

  32. European Medicines Agency. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines. Amsterdam: EMA; 2020 [acceso 08/06/2022]. p. 11. Disponible en: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-COVID-19/

  33. CIGB. Manual del Producto Candidato Vacunal Abdala. La Habana, Cuba: CIGB; 2021.

  34. Martin K, Bégaud B, Latry P, Miremont Salamé G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004 [acceso 08/06/2022];57(1):86-92:12. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14678345/

  35. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. Cap 3. 2 ed. Geneva, Switzerland: WHO; 2018 [acceso 08/06/2022]. Disponible en: https://vacunasaep.org/documentos/manual/cap-3




2020     |     www.medigraphic.com